Clinical trial

An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection

NCT02972450

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2019-02-20

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2019-02-20Date precision: day

Registry last updated2019-08-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIV-1-infectionunresolved

Interventions

GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccineBIOLOGICAL

GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ VedolizumabBIOLOGICAL

Vedolizumab 300 MG [Entyvio]DRUG · verified · RxNorm: vedolizumab 300 MG [Entyvio]

Sponsors & collaborators

ANRS, Emerging Infectious Diseaseslead sponsor

European Commissioncollaborator

Swiss Governmentcollaborator

Medical Research Councilcollaborator

FIT Biotech Ltd.collaborator

Fred Hutchinson Cancer Centercollaborator

University College, Londoncollaborator

Centre Hospitalier Universitaire Vaudoiscollaborator

Imperial College Londoncollaborator

Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCScollaborator

Universitätsklinikum Hamburg-Eppendorfcollaborator

Institut d'Investigacions Biomèdiques August Pi i Sunyercollaborator

Henri Mondor University Hospitalcollaborator

European Georges Pompidou Hospitalcollaborator

Saint-Louis Hospital, Paris, Francecollaborator

Mapped research locations

LondonUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02972450 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.